Current Management of Rheumatoid Arthritis: Focus on Conventional DMARD
MetadataShow full item record
Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis in adults. RA has a significant negative impact on the ability to perform daily activities, including work and household tasks, and health related quality of life, and it increases mortality.1It is characterized by symmetric polyarticular inflammation of the synovium, typically of the small joints of the hands (MCP and PIP), wrists and feet. This inflammation results in pain and stiffness, and can lead to progressive joint damage resulting in deformities and loss of function. Associated organ damage also contributes to severe disability. Additionally, chronic inflammation secondary to RA can lead to an increased risk of cardiovascular disease and changes in bone metabolism.2 Clinical diagnosis of RA is very complex and in volves many features that are difficult to help the clinical diagnosis. American college of rheumatology has introduced the formal criteria to diagnose RA in early stages. Because of the nature of autoimmune arthritis, effective and complete suppression of the disease has been the early therapeutic goal.3Recently, treatment of the RA has considerable progressdue to the advent of new tools and new treatment that have been made and accredited, highlighting the need for guide lines focused on primary RA. The goal of treatment should now betoget clinical progression for preventing structural damage and inability. Currently, available treatment options include nonsteroidal anti-inflammatory drug (NSAIDs), glucocorticoids(GC) that are a group of steroid hormones, disease- modifyinganti-rheumatic drugs (DMARDs), biological agents including monoclonal antibodies and small molecules, bisphosphonate therapy, nano technology, oraltolerance, photodynamic therapy, gene therapy, bone marrow transplantation, liposomes, super paramagnetic iron oxide nano particles (SPIONs).